Mazdutide vs Tesofensine
Head-to-head comparison of Mazdutide and Tesofensine for research applications. Both peptides are studied for various research applications, but they differ significantly in mechanism and evidence level.
Side-by-Side Comparison
| Attribute | Mazdutide | Tesofensine |
|---|---|---|
| Category | Metabolic / Dual GLP-1/Glucagon Agonist | Weight Loss / Reuptake Inhibitor |
| Mechanism | Mazdutide is a fatty acid-acylated peptide that activates both the GLP-1 receptor and the glucagon receptor. | Tesofensine inhibits the presynaptic reuptake of serotonin, norepinephrine, and dopamine, increasing synaptic concentrations of all three monoamines. |
| Evidence Rating | C — Phase I–II Clinical Trials | C — Phase II–III Clinical Trials |
| Clinical Status | Approved in China (June 2024) for chronic weight management. Phase III in China for T2D. Not yet approved outside China. | Phase 3 clinical trials (Saniona). Phase 2 completed with significant weight loss results. |
| Safety Profile | Common: GI side effects including nausea, vomiting, diarrhea (similar to GLP-1 agonist class); GI adverse events are dose-dependent and generally transient | Phase 2 trials reported increased heart rate (5-8 bpm) and blood pressure elevation at higher doses; Common side effects: dry mouth, insomnia, constipation, nausea, diarrhea |
| Molecular Weight | ~4233.7 g/mol | ~397.5 g/mol |
| Half-Life | Suitable for once-weekly dosing (exact value not fully published) | N/A |
Overview
Mazdutide and Tesofensine are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, and safety profiles to help researchers understand the key differences and overlaps.
Mazdutide — Mechanism & Evidence
Mazdutide (IBI362) is a dual GLP-1/glucagon receptor agonist co-developed by Innovent Biologics and Eli Lilly (MW 4,563.06 g/mol). It is a once-weekly injectable peptide that activates both GLP-1 and glucagon receptors, aiming to combine GLP-1-mediated appetite suppression and glucose lowering with glucagon-mediated increases in energy expenditure and hepatic fat reduction. China's NMPA approved mazdutide in June 2025 for chronic weight management and in September 2025 for glycaemic control in type 2 diabetes, making it the first dual GLP-1/glucagon agonist approved anywhere in the world.
Key claims: Significant weight loss in Chinese adults with obesity; Effective glycemic control; Reduces hepatic fat content.
Tesamorelin 10mg
10mg
Tesofensine — Mechanism & Evidence
Tesofensine is a triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine) originally developed for Alzheimer's and Parkinson's disease. The compound was developed by NeuroSearch A/S and later licensed to Saniona, which is pursuing Phase 3 trials.
Key claims: Produces significant weight loss (~10% body weight); Suppresses appetite and reduces caloric intake; Increases resting metabolic rate.
Shared Research Applications
These peptides target different research areas. Mazdutide focuses on Weight Management, Metabolic Health, while Tesofensine targets Weight Loss, Appetite Suppression.
Safety Considerations
Mazdutide: Common: GI side effects including nausea, vomiting, diarrhea (similar to GLP-1 agonist class) GI adverse events are dose-dependent and generally transient Heart rate increase observed, consistent with GLP-1 agonist class effect
Tesofensine: Phase 2 trials reported increased heart rate (5-8 bpm) and blood pressure elevation at higher doses Common side effects: dry mouth, insomnia, constipation, nausea, diarrhea Psychiatric effects reported: anxiety, mood changes (consistent with monoamine reuptake inhibitors)
Shop Research Peptides
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.